stocks

Abbott Laboratories’ third quarter 2019 earnings came in line with the market’s projections, while sales missed the expectations. The pharma company reported adjusted EPS of $0.84 on sales of $8.08 billion. Wall Street had forecasted Abbott to post earnings of $0.84 on sales of $8.11 billion...

Healthcare giant Johnson & Johnson (JNJ) reported a beat on both the top and bottom line expectations as it posted its Q2 2018 earnings. This was aided by a double-digit growth in Pharmaceutical business and the accelerating sales momentum in the Medical Devices business...

Just days after FDA announced a list of companies that use “gaming” tactics to delay the entry of the generic competitors, Celgene plunges to a new 52-week low. Celgene topped FDA’s list with 31 complaints. https://news.alphastreet.com/celgene-plunges-to-a-new-52-week-low-battered-by-setbacks/

Mylan reported yet another quarter of declining sales, a trend the company has been seeing for the last couple of quarters. The sales decline was marred by increased competition and the continuing declining sales of the company’s allergy drug EpiPen, which in turn resulted in a 19% decline in...

Alexion reported a rise in Q1 2018 earnings and revenue, and lifted the guidance for the year. Along with this, the company also reported a positive top line results for its Phase 3 study. The company that specializes in manufacturing drugs for rare disorder reported a 7% increase in its revenue...

AbbVie’s first quarter results topped analyst consensus both on earnings and sales front, driven by double-digit sales growth from Humira, Imbruvica, and HCV. Sales improved 21.4% to $7.9 billion, while adjusted earnings came in at $1.87, up 46%. The company also has decided to buyback shares to...

Biogen, whose shares fell nearly 16.5% this year, saw it further dip 2.4% to $259.30 in pre-market trade, despite the strong first-quarter earnings. Earnings, excluding items, jumped to $6.05 per share this quarter from last year’s $5.20 per share. On a diluted basis, Biogen reported earnings of...

Johnson & Johnson may not be having a great 2018 so far with the stock ticking down about 8% since the year started. But is it time to get rid of the world’s largest pharma company’s shares? Let’s see.

Non-cash goodwill and asset impairment charges in the DMG reportable segment hurt DaVita's Q3 2017 results. Total U.S. dialysis treatments for 3Q17 were 7.2 million. As of Sept. 30, 2017, DaVita provided dialysis services to a total of about 218,200 patients. Graphical view of results...

Cardinal Health (CAH) earnings for the first quarter of 2018 are hurt by restructuring costs from regaining direct distribution of self-manufactured surgeon gloves and higher intangible assets amortization. Despite this, the company reaffirmed its full-year 2018 non-GAAP EPS guidance. Graphical...

CVS health profit was hit due to temporary store closure that occurred during Hurricane Harvey. Few of its stores are still recovering from the affect of the hurricane. Atena is said to have a medical membership of over 20 Million. If the two companies pair up, cvs could open the pharmacy...